Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-50002 in Alopecia Universalis and Alopecia Totalis
NCT03315689Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Dec 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifidancitinib in alopecia universalis (AU), alopecia totalis (AT), sponsored by Aclaris Therapeutics, Inc.. Started Dec 2017; status: completed.
02
Drugs
ifidancitinib
03
Conditions
alopecia universalis (AU)alopecia totalis (AT)
Beyond the preview
Go deeper on NCT03315689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315689.